NR 546 ADVANCED PSYCHOPHARMACOLOGY| EXAM COMPLETE QUESTIONS WITH
VERIFIED SOLUTIONS - UPDATED VERSION 2026/2027
Psychiatric-Mental Health Nurse Practitioner
Q1. What are the four main pharmacokinetic processes?
Answer: Absorption, Distribution, Metabolism, and Excretion (ADME). These
processes determine the drug concentration at the site of action over time.
Q2. What is the blood-brain barrier (BBB) and why is it important in
psychopharmacology?
Answer: The BBB is a selective, semipermeable barrier formed by tight
junctions between endothelial cells lining brain capillaries. It restricts passage
of many substances into the CNS; psychotropic drugs must be lipophilic or
use active transport to cross it.
Q3. Define bioavailability and explain how it affects drug dosing.
Answer: Bioavailability is the fraction of an administered drug that reaches
systemic circulation unchanged. Low oral bioavailability (e.g., due to first-pass
metabolism) requires higher oral doses versus parenteral routes to achieve
therapeutic levels.
Q4. What is first-pass metabolism?
Answer: First-pass metabolism (hepatic first pass) is the phenomenon where
a drug is extensively metabolized in the liver before reaching systemic
circulation, significantly reducing the bioavailable dose. It is relevant for many
antidepressants and antipsychotics.
NR 546 Psychopharmacology – 300 Q&A Study Guide
,Q5. What is the volume of distribution (Vd) and what does a high Vd
indicate?
Answer: Vd is the theoretical volume needed to contain the total drug in the
body at the observed plasma concentration. A high Vd (e.g., chlorpromazine
>20 L/kg) indicates extensive tissue binding, making the drug difficult to
remove by dialysis.
Q6. Define half-life (t½) and its clinical significance.
Answer: t½ is the time required for plasma concentration to decrease by
50%. It determines dosing frequency, time to steady state (~5 half-lives), and
duration of drug effects after discontinuation.
Q7. What is steady state and when is it achieved?
Answer: Steady state is achieved when the rate of drug administration equals
the rate of elimination. It is reached after approximately 5 half-lives, at which
point plasma levels remain relatively constant with regular dosing.
Q8. Explain the cytochrome P450 (CYP450) enzyme system and its
relevance to psychopharmacology.
Answer: CYP450 enzymes are liver (and gut) enzymes responsible for
oxidative metabolism of most psychotropic drugs. Key isoforms include
CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Drug interactions arise
when one drug inhibits or induces these enzymes.
Q9. What is a CYP2D6 poor metabolizer and what are its clinical
implications?
Answer: A poor metabolizer has reduced CYP2D6 activity due to genetic
polymorphisms (~7–10% of Caucasians). They accumulate drugs metabolized
by CYP2D6 (e.g., tricyclic antidepressants, many antipsychotics), risking
toxicity at standard doses.
Q10. What is pharmacodynamic tolerance?
Answer: Pharmacodynamic tolerance occurs when the target receptor or
effector system adapts to ongoing drug exposure, requiring higher doses to
achieve the same effect. It results from receptor downregulation,
desensitization, or compensatory changes in downstream signaling.
NR 546 Psychopharmacology – 300 Q&A Study Guide
,Q11. Describe the difference between agonist, partial agonist, and
antagonist.
Answer: An agonist fully activates a receptor; a partial agonist activates with
less than maximal efficacy; an antagonist binds without activating and blocks
agonist effects. Partial agonists (e.g., aripiprazole) can act as functional
agonists or antagonists depending on the endogenous tone.
Q12. What is the therapeutic index (TI) and why is it important?
Answer: TI = TD50/ED50. A narrow TI (e.g., lithium, clozapine) means
therapeutic and toxic doses are close together, requiring blood level
monitoring and careful dosing. Drugs with wide TI are generally safer.
Q13. Explain protein binding and its effects on drug activity.
Answer: Many psychotropic drugs are highly protein-bound (primarily to
albumin). Only unbound (free) drug is pharmacologically active. Conditions
lowering albumin (malnutrition, hepatic disease) increase free drug and risk of
toxicity.
Q14. What is the concept of receptor affinity versus efficacy?
Answer: Affinity refers to the strength of drug-receptor binding (measured by
Ki or Kd). Efficacy (intrinsic activity) is the ability to produce a biological
response once bound. A drug can have high affinity but low or no efficacy
(e.g., antagonists).
Q15. What are the key differences between Phase I and Phase II drug
metabolism?
Answer: Phase I reactions (oxidation, reduction, hydrolysis) introduce or
unmask functional groups, often via CYP450 enzymes. Phase II reactions
(glucuronidation, sulfation, acetylation) conjugate the drug to increase water
solubility for excretion.
Unit 2: Neurotransmitter Systems
Q16. Describe the serotonin (5-HT) system and its relevance to psychiatric
disorders.
NR 546 Psychopharmacology – 300 Q&A Study Guide
, Answer: Serotonergic neurons originate primarily in the raphe nuclei and
project widely throughout the brain. Serotonin regulates mood, sleep, appetite,
cognition, and anxiety. Dysregulation is implicated in depression, anxiety
disorders, OCD, and schizophrenia.
Q17. What are the key dopamine pathways and their clinical relevance?
Answer: Major dopamine pathways: mesolimbic (reward, implicated in
psychosis/addiction), mesocortical (cognition/affect, implicated in negative
symptoms of schizophrenia), nigrostriatal (motor control, implicated in EPS),
and tuberoinfundibular (prolactin regulation).
Q18. What is the role of norepinephrine in psychiatric disorders?
Answer: Norepinephrine (NE) originates from the locus coeruleus and
modulates attention, arousal, fight-or-flight response, and mood.
Dysregulation contributes to depression, anxiety, PTSD, and ADHD. It is
targeted by SNRIs, TCAs, and atomoxetine.
Q19. Explain the role of glutamate in neuropsychiatric disorders.
Answer: Glutamate is the primary excitatory neurotransmitter acting at AMPA,
NMDA, and mGluR receptors. NMDA hypofunction is hypothesized in
schizophrenia. Excessive glutamate causes excitotoxicity in
neurodegenerative diseases. Memantine blocks NMDA receptors.
Q20. What is the role of GABA in neuropsychiatric disorders?
Answer: GABA is the primary inhibitory neurotransmitter. GABAergic deficits
contribute to anxiety, epilepsy, and potentially schizophrenia.
Benzodiazepines, barbiturates, and many anticonvulsants enhance GABA
activity at GABA-A receptors.
Q21. Describe the acetylcholine system and its relevance to
psychopharmacology.
Answer: Cholinergic neurons (in the basal forebrain, brainstem) modulate
memory, learning, and REM sleep. Muscarinic blockade causes
anticholinergic side effects (dry mouth, urinary retention, confusion).
Cholinesterase inhibitors (e.g., donepezil) enhance ACh in Alzheimer's
disease.
NR 546 Psychopharmacology – 300 Q&A Study Guide
VERIFIED SOLUTIONS - UPDATED VERSION 2026/2027
Psychiatric-Mental Health Nurse Practitioner
Q1. What are the four main pharmacokinetic processes?
Answer: Absorption, Distribution, Metabolism, and Excretion (ADME). These
processes determine the drug concentration at the site of action over time.
Q2. What is the blood-brain barrier (BBB) and why is it important in
psychopharmacology?
Answer: The BBB is a selective, semipermeable barrier formed by tight
junctions between endothelial cells lining brain capillaries. It restricts passage
of many substances into the CNS; psychotropic drugs must be lipophilic or
use active transport to cross it.
Q3. Define bioavailability and explain how it affects drug dosing.
Answer: Bioavailability is the fraction of an administered drug that reaches
systemic circulation unchanged. Low oral bioavailability (e.g., due to first-pass
metabolism) requires higher oral doses versus parenteral routes to achieve
therapeutic levels.
Q4. What is first-pass metabolism?
Answer: First-pass metabolism (hepatic first pass) is the phenomenon where
a drug is extensively metabolized in the liver before reaching systemic
circulation, significantly reducing the bioavailable dose. It is relevant for many
antidepressants and antipsychotics.
NR 546 Psychopharmacology – 300 Q&A Study Guide
,Q5. What is the volume of distribution (Vd) and what does a high Vd
indicate?
Answer: Vd is the theoretical volume needed to contain the total drug in the
body at the observed plasma concentration. A high Vd (e.g., chlorpromazine
>20 L/kg) indicates extensive tissue binding, making the drug difficult to
remove by dialysis.
Q6. Define half-life (t½) and its clinical significance.
Answer: t½ is the time required for plasma concentration to decrease by
50%. It determines dosing frequency, time to steady state (~5 half-lives), and
duration of drug effects after discontinuation.
Q7. What is steady state and when is it achieved?
Answer: Steady state is achieved when the rate of drug administration equals
the rate of elimination. It is reached after approximately 5 half-lives, at which
point plasma levels remain relatively constant with regular dosing.
Q8. Explain the cytochrome P450 (CYP450) enzyme system and its
relevance to psychopharmacology.
Answer: CYP450 enzymes are liver (and gut) enzymes responsible for
oxidative metabolism of most psychotropic drugs. Key isoforms include
CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. Drug interactions arise
when one drug inhibits or induces these enzymes.
Q9. What is a CYP2D6 poor metabolizer and what are its clinical
implications?
Answer: A poor metabolizer has reduced CYP2D6 activity due to genetic
polymorphisms (~7–10% of Caucasians). They accumulate drugs metabolized
by CYP2D6 (e.g., tricyclic antidepressants, many antipsychotics), risking
toxicity at standard doses.
Q10. What is pharmacodynamic tolerance?
Answer: Pharmacodynamic tolerance occurs when the target receptor or
effector system adapts to ongoing drug exposure, requiring higher doses to
achieve the same effect. It results from receptor downregulation,
desensitization, or compensatory changes in downstream signaling.
NR 546 Psychopharmacology – 300 Q&A Study Guide
,Q11. Describe the difference between agonist, partial agonist, and
antagonist.
Answer: An agonist fully activates a receptor; a partial agonist activates with
less than maximal efficacy; an antagonist binds without activating and blocks
agonist effects. Partial agonists (e.g., aripiprazole) can act as functional
agonists or antagonists depending on the endogenous tone.
Q12. What is the therapeutic index (TI) and why is it important?
Answer: TI = TD50/ED50. A narrow TI (e.g., lithium, clozapine) means
therapeutic and toxic doses are close together, requiring blood level
monitoring and careful dosing. Drugs with wide TI are generally safer.
Q13. Explain protein binding and its effects on drug activity.
Answer: Many psychotropic drugs are highly protein-bound (primarily to
albumin). Only unbound (free) drug is pharmacologically active. Conditions
lowering albumin (malnutrition, hepatic disease) increase free drug and risk of
toxicity.
Q14. What is the concept of receptor affinity versus efficacy?
Answer: Affinity refers to the strength of drug-receptor binding (measured by
Ki or Kd). Efficacy (intrinsic activity) is the ability to produce a biological
response once bound. A drug can have high affinity but low or no efficacy
(e.g., antagonists).
Q15. What are the key differences between Phase I and Phase II drug
metabolism?
Answer: Phase I reactions (oxidation, reduction, hydrolysis) introduce or
unmask functional groups, often via CYP450 enzymes. Phase II reactions
(glucuronidation, sulfation, acetylation) conjugate the drug to increase water
solubility for excretion.
Unit 2: Neurotransmitter Systems
Q16. Describe the serotonin (5-HT) system and its relevance to psychiatric
disorders.
NR 546 Psychopharmacology – 300 Q&A Study Guide
, Answer: Serotonergic neurons originate primarily in the raphe nuclei and
project widely throughout the brain. Serotonin regulates mood, sleep, appetite,
cognition, and anxiety. Dysregulation is implicated in depression, anxiety
disorders, OCD, and schizophrenia.
Q17. What are the key dopamine pathways and their clinical relevance?
Answer: Major dopamine pathways: mesolimbic (reward, implicated in
psychosis/addiction), mesocortical (cognition/affect, implicated in negative
symptoms of schizophrenia), nigrostriatal (motor control, implicated in EPS),
and tuberoinfundibular (prolactin regulation).
Q18. What is the role of norepinephrine in psychiatric disorders?
Answer: Norepinephrine (NE) originates from the locus coeruleus and
modulates attention, arousal, fight-or-flight response, and mood.
Dysregulation contributes to depression, anxiety, PTSD, and ADHD. It is
targeted by SNRIs, TCAs, and atomoxetine.
Q19. Explain the role of glutamate in neuropsychiatric disorders.
Answer: Glutamate is the primary excitatory neurotransmitter acting at AMPA,
NMDA, and mGluR receptors. NMDA hypofunction is hypothesized in
schizophrenia. Excessive glutamate causes excitotoxicity in
neurodegenerative diseases. Memantine blocks NMDA receptors.
Q20. What is the role of GABA in neuropsychiatric disorders?
Answer: GABA is the primary inhibitory neurotransmitter. GABAergic deficits
contribute to anxiety, epilepsy, and potentially schizophrenia.
Benzodiazepines, barbiturates, and many anticonvulsants enhance GABA
activity at GABA-A receptors.
Q21. Describe the acetylcholine system and its relevance to
psychopharmacology.
Answer: Cholinergic neurons (in the basal forebrain, brainstem) modulate
memory, learning, and REM sleep. Muscarinic blockade causes
anticholinergic side effects (dry mouth, urinary retention, confusion).
Cholinesterase inhibitors (e.g., donepezil) enhance ACh in Alzheimer's
disease.
NR 546 Psychopharmacology – 300 Q&A Study Guide
